Viracta Therapeutics (STU:RYIS) Debt-to-Equity : 1.70 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Viracta Therapeutics Debt-to-Equity?

Viracta Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €17.35 Mil. Viracta Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.00 Mil. Viracta Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2024 was €10.19 Mil. Viracta Therapeutics's debt to equity for the quarter that ended in Mar. 2024 was 1.70.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Viracta Therapeutics's Debt-to-Equity or its related term are showing as below:

STU:RYIS' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.13 Med: 0.07 Max: 1.7
Current: 1.7

During the past 4 years, the highest Debt-to-Equity Ratio of Viracta Therapeutics was 1.70. The lowest was -0.13. And the median was 0.07.

STU:RYIS's Debt-to-Equity is ranked worse than
94.1% of 1068 companies
in the Biotechnology industry
Industry Median: 0.14 vs STU:RYIS: 1.70

Viracta Therapeutics Debt-to-Equity Historical Data

The historical data trend for Viracta Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viracta Therapeutics Debt-to-Equity Chart

Viracta Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

-0.13

0.06

0.41

1.40

Viracta Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial												0.50	0.63	0.85	1.40	1.70

Competitive Comparison of Viracta Therapeutics's Debt-to-Equity

For the Biotechnology subindustry, Viracta Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Viracta Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Viracta Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Viracta Therapeutics's Debt-to-Equity falls into.

Viracta Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Viracta Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(23.435	+	0)	/	16.799
	=	1.40

Viracta Therapeutics's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(17.348	+	0)	/	10.194
	=	1.70

Viracta Therapeutics (STU:RYIS) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Viracta Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Viracta Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Viracta Therapeutics (STU:RYIS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viracta Therapeutics Inc (STU:RYIS) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

VIRX:USA

Address

2533 South Coast Highway 101, Suite 210, Cardiff, CA, USA, 92007

Website

https://www.viracta.com

Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. Its lead product candidate is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people who have received organ transplants.

Viracta Therapeutics (STU:RYIS) Headlines

No Headlines